Chang Gon Kim

List of Publications by Year
in descending order

46 papers	1,408 citations

430442
18
h-index

360668
35
g-index

46 all docs	46 docs citations

46
times ranked

2630
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor. Yonsei Medical Journal, 2022, 63, 42.	0.9	7
2	Patritumab Deruxtecan: Paving the Way for EGFR-TKI–Resistant NSCLC. Cancer Discovery, 2022, 12, 16-19.	7.7	7
3	Antibody–Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Non–Small Cell Lung Cancer. Cancer Research, 2022, 82, 18-20.	0.4	5
4	Predicting treatment outcomes using ^{18}F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110687.	1.4	7
5	Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis.. Journal of Clinical Oncology, 2022, 40, 330-330.	0.8	1
6	Disproportional enrichment of FoxP3^{+}CD4^{+} regulatory T cells shapes a suppressive tumour microenvironment in head and neck squamous cell carcinoma. Clinical and Translational Medicine, 2022, 12, e753.	1.7	2
7	Phase II Clinical Trial of Eribulin–Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma. Clinical Cancer Research, 2022, 28, 3225-3234.	3.2	5
8	Abstract LB544: Targeting adaptive metabolic program as a novel treatment approach for TKIs-failed ALK-positive NSCLCs. Cancer Research, 2022, 82, LB544-LB544.	0.4	0
9	The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211132.	1.4	10
10	Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC): Updated results with high dimensional profiling of circulating immune cells.. Journal of Clinical Oncology, 2022, 40, 6072-6072.	0.8	1
11	PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15. Cellular and Molecular Immunology, 2021, 18, 385-397.	4.8	37
12	Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. Journal of Hepatology, 2021, 74, 350-359.	1.8	122
13	Dynamic changes in circulating PD-1+CD8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer. European Journal of Cancer, 2021, 143, 113-126.	1.3	30
14	Characterization of hyperprogressive disease in patients with advanced biliary tract cancer treated with anti-PD-1 inhibitor: A multicenter retrospective study.. Journal of Clinical Oncology, 2021, 39, 339-339.	0.8	0
15	Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma. Clinical Cancer Research, 2021, 27, 2947-2958.	3.2	24
16	Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target?. Journal of Thoracic Oncology, 2021, 16, 709-711.	0.5	2
17	Eribulin and gemcitabine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A multicenter, single-arm, phase 2-trial.. Journal of Clinical Oncology, 2021, 39, 11516-11516.	0.8	1
18	On-treatment derived neutrophil-to-lymphocyte ratio and response to palbociclib and letrozole: Analysis of a multicenter retrospective cohort and the PALOMA-2 study.. Journal of Clinical Oncology, 2021, 39, 1066-1066.	0.8	0

#	Article	IF	Citations
19	Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (HER-RAM study).. Journal of Clinical Oncology, 2021, 39, 4063-4063.	0.8	1
20	Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma. Clinical Cancer Research, 2021, 27, 4397-4409.	3.2	49
21	Clinical decision support algorithm based on machine learning to assess the clinical response to anti–programmed death-1 therapy in patients with non–small-cell lung cancer. European Journal of Cancer, 2021, 153, 179-189.	1.3	16
22	Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer. , 2021, 9, e002780.		15
23	4–1BB Delineates Distinct Activation Status of Exhausted Tumor–infiltrating CD8+ T Cells in Hepatocellular Carcinoma. Hepatology, 2020, 71, 955-971.	3.6	70
24	Functions of human liver CD69+CD103-CD8+ T cells depend on HIF-2α activity in healthy and pathologic livers. Journal of Hepatology, 2020, 72, 1170-1181.	1.8	39
25	Clinical Significance of Preoperative Serum Carcinoembryonic Antigen Within the Normal Range in Colorectal Cancer Patients Undergoing Curative Resection. Annals of Surgical Oncology, 2020, 27, 2774-2783.	0.7	12
26	PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors. Clinical Cancer Research, 2020, 26, 1644-1655.	3.2	25
27	Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.. Journal of Clinical Oncology, 2020, 38, 550-550.	0.8	3
28	Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy. Immune Network, 2020, 20, e8.	1.6	19
29	Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. Cancer Medicine, 2019, 8, 5023-5032.	1.3	25
30	VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers. Science Immunology, 2019, 4, .	5.6	148
31	Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8+ T Cells is Determined by Their Differentiation Status in Glioblastoma. Clinical Cancer Research, 2019, 25, 2549-2559.	3.2	46
32	Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma. OncoImmunology, 2019, 8, e1525243.	2.1	46
33	STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. Journal of Clinical Investigation, 2019, 129, 4350-4364.	3.9	178
34	A machine learning based prediction model of anti-PD-1 therapy response using noninvasive clinical information and blood markers of lung cancer patients.. Journal of Clinical Oncology, 2019, 37, e14138-e14138.	0.8	1
35	YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma. Cancer Immunology Research, 2018, 6, 255-266.	1.6	158
36	Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Head and Neck, 2018, 40, 55-62.	0.9	26

#	Article	IF	Citations
37	Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma. Cancer Research and Treatment, 2018, 50, 1238-1251.	1.3	10
38	Osteosarcoma in a Patient With Pseudohypoparathyroidism Type 1b Due to Paternal Uniparental Disomy of Chromosome 20q. Journal of Bone and Mineral Research, 2017, 32, 770-775.	3.1	8
39	Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer. Annals of Surgical Oncology, 2017, 24, 227-235.	0.7	39
40	IMMU-16. EFFECT OF ANTI-PD-1 THERAPY COMBINATION ON TEMOZOLOMIDE IN MOUSE GLIOBLASTOMA. Neuro-Oncology, 2017, 19, vi116-vi116.	0.6	1
41	Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery. BMC Cancer, 2017, 17, 615.	1.1	9
42	Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis. Oncotarget, 2017, 8, 65111-65122.	0.8	23
43	Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy. Journal of Breast Cancer, 2016, 19, 76.	0.8	18
44	Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. British Journal of Cancer, 2016, 115, 25-33.	2.9	129
45	Benefit of Adjuvant Chemotherapy After Curative Resection of Lung Metastasis in Colorectal Cancer. Annals of Surgical Oncology, 2016, 23, 928-935.	0.7	28
46	Clinical trials outcomes of combined BKM120 and cetuximab compared to BKM120 in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M-SCCHN).. Journal of Clinical Oncology, 2015, 33, 6049-6049.	0.8	5